Moleculin Biotech, Inc. (MBRX)
NASDAQ: MBRX · Real-Time Price · USD
2.450
-0.100 (-3.92%)
Nov 4, 2024, 4:00 PM EST - Market closed
Moleculin Biotech Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Current | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
Nov '24 Nov 4, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Market Capitalization | 7 | 29 | 30 | 53 | 50 | 42 | |
Market Cap Growth | -52.63% | -5.48% | -42.91% | 5.47% | 20.43% | 48.31% | |
Enterprise Value | -3 | 5 | -20 | -22 | 38 | 27 | |
Last Close Price | 2.45 | 12.88 | 15.90 | 27.90 | 71.74 | 82.36 | |
PE Ratio | - | -0.85 | -1.04 | -3.15 | -2.71 | -2.82 | |
PB Ratio | 0.35 | 1.10 | 0.58 | 0.67 | 2.84 | 2.69 | |
P/FCF Ratio | -0.32 | -1.18 | -1.10 | -2.80 | -2.78 | -2.43 | |
P/OCF Ratio | -0.32 | -1.19 | -1.10 | -2.80 | -2.84 | -2.43 | |
EV/EBITDA Ratio | 0.29 | -0.16 | 0.64 | 0.96 | -1.94 | -1.55 | |
EV/EBIT Ratio | 0.29 | -0.16 | 0.64 | 0.95 | -1.92 | -1.53 | |
EV/FCF Ratio | 0.32 | -0.19 | 0.71 | 1.15 | -2.09 | -1.56 | |
Debt / Equity Ratio | 0.03 | 0.02 | 0.01 | 0.00 | 0.02 | 0.02 | |
Debt / FCF Ratio | -0.02 | -0.02 | -0.02 | -0.01 | -0.02 | -0.02 | |
Quick Ratio | 1.89 | 3.47 | 8.96 | 19.59 | 5.20 | 3.01 | |
Current Ratio | 2.39 | 3.86 | 9.46 | 20.02 | 5.89 | 3.78 | |
Return on Equity (ROE) | -86.82% | -76.07% | -44.25% | -32.85% | -104.14% | -88.50% | |
Return on Assets (ROA) | -47.68% | -38.73% | -27.06% | -25.38% | -45.48% | -48.87% | |
Return on Capital (ROIC) | -58.95% | -46.71% | -29.06% | -29.54% | -72.61% | -72.48% | |
Earnings Yield | -361.12% | -103.79% | -95.65% | -29.90% | -34.44% | -31.56% | |
FCF Yield | -369.43% | -84.46% | -91.30% | -35.69% | -36.01% | -41.22% | |
Buyback Yield / Dilution | -16.88% | -3.60% | -6.43% | -172.97% | -45.07% | -57.20% | |
Total Shareholder Return | -16.88% | -3.60% | -6.43% | -172.97% | -45.07% | -57.20% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.